Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment

Despite the well described heterogeneity in glioblastoma (GBM), treatment is standardized, and clinical trials investigate treatment effects at population level. Genomics-driven oncology for stratified treatme...

Source: Clinical and Translational Medicine - December 30, 2019 Category: Internal Medicine Authors: Erlend Skaga, Evgeny Kulesskiy, Marit Brynjulvsen, Cecilie J. Sandberg, Swapnil Potdar, Iver A. Langmoen, Aki Laakso, Em ília Gaál-Paavola, Markus Perola, Krister Wennerberg and Einar O. Vik-Mo Tags: Research Source Type: research